Patents by Inventor Bryon Merrill

Bryon Merrill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amido ether substituted imidazoquinolines
    Publication number: 20030096835
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: December 6, 2001
    Publication date: May 22, 2003
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
  • Urea substituted imidazopyridines
    Patent number: 6545017
    Abstract: Imidazopyridine compounds that contain urea or thiourea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: April 8, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Joseph F. Dellaria, Chad A. Haraldson, Philip D. Heppner, Kyle J. Lindstrom, Bryon A. Merrill
  • Amide substituted imidazopyridines
    Patent number: 6545016
    Abstract: Imidazopyridine compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: April 8, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Joseph F. Dellaria, Chad A. Haraldson, Philip D. Heppner, Kyle J. Lindstrom, Bryon A. Merrill
  • Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
    Publication number: 20030064968
    Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
    Type: Application
    Filed: September 12, 2002
    Publication date: April 3, 2003
    Applicant: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Urea substituted imidazoquinolines
    Patent number: 6541485
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: April 1, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, Bryon A. Merrill, Michael J. Rice
  • Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
    Publication number: 20030045545
    Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
    Type: Application
    Filed: September 12, 2002
    Publication date: March 6, 2003
    Applicant: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Sulfonamido substituted imidazopyridines
    Patent number: 6525064
    Abstract: Imidazopyridine compounds that contain sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: February 25, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Joseph F. Dellaria, Chad A. Haraldson, Philip D. Heppner, Kyle J. Lindstrom, Bryon A. Merrill
  • Imidazonaphthyridines
    Patent number: 6514985
    Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: February 4, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Stephen L. Crooks, Philip D. Heppner, Gregory J. Marszalek, Peter V. Maye, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Sulfonamido ether substituted imidazoquinolines
    Publication number: 20020193396
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: December 1, 2001
    Publication date: December 19, 2002
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill, Ralph R. Roberts, Ai-Ping Wei
  • Thioether substituted imidazoquinolines
    Publication number: 20020173655
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: December 6, 2001
    Publication date: November 21, 2002
    Inventors: Joseph F. Dellaria, Bryon A. Merrill, Matthew R. Radmer
  • Imidazonaphthyridines
    Publication number: 20020173654
    Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Application
    Filed: August 31, 2001
    Publication date: November 21, 2002
    Applicant: 3M Innovative Properties Company
    Inventors: Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
  • Amide substituted imidazoquinolines
    Patent number: 6451810
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: September 17, 2002
    Assignee: 3M Innovative Properties Company
    Inventors: Patrick L. Coleman, Stephen L. Crooks, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
  • Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
    Patent number: 6440992
    Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: August 27, 2002
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
    Publication number: 20020072528
    Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
    Type: Application
    Filed: September 24, 2001
    Publication date: June 13, 2002
    Applicant: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Sulfonamide and sulfamide substituted imidazoquinolines
    Patent number: 6331539
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: December 18, 2001
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
  • Oxazolo, thiazolo and selenazolo [4,5-c] quinolin-4-amines and analogs thereof
    Patent number: 6323200
    Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: November 27, 2001
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Imidazonaphthyridines
    Patent number: 6194425
    Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Grant
    Filed: December 11, 1998
    Date of Patent: February 27, 2001
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Stephen L. Crooks, Philip D. Heppner, Gregory J. Marszalek, Peter V. Maye, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Bishydroxyureas
    Patent number: 6121323
    Abstract: Bishydroxyureas are provided that inhibit the enzyme 5-lipoxygenase. These compounds have the formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, A and M are defined herein. Also disclosed are pharmaceutical compositions containing such compounds and methods of inhibiting the enzyme 5-lipoxygenase using such compounds.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: September 19, 2000
    Assignee: 3M Innovative Properties Company
    Inventor: Bryon A. Merrill
  • Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
    Patent number: 6110929
    Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: August 29, 2000
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Method of inhibiting leukotriene biosynthesis
    Patent number: 5612377
    Abstract: A method of inhibiting leukotriene biosynthesis, involving administering a compound of the formula: ##STR1## wherein M, R, R', R", and n are as defined herein. Also, a pharmaceutical composition involving such a compound and the use of such compounds in the manufacture of a pharmaceutical composition for inhibiting leukotriene biosynthesis.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: March 18, 1997
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Stephen L. Crooks, Bryon A. Merrill, Paul D. Wightman